2024 ASH Annual Meeting
The 66th American Society of Hematology Annual Meeting and Exposition, held December 7-10, 2024, in San Diego, California, featured plenary lectures, expert sessions, poster presentations, and much more. Find highlights from the sessions that are most relevant to oncology nurses.
Learn how oral dysbiosis correlates with exacerbated cGVHD in patients after receiving hematopoietic cell transplantation.
Prithviraj Bose, MD, unpacks key highlights in MPN treatment and research at ASH 2024.
Amy Pierre, RN, BSN, ANP-BC, explains why it's important for advanced practice nurses to be invovled in research.
Lisa Hwa, APRN, CNP, DNP, MS, is a member of the ASH Medical Educators Institute and has presented multiple ASH abstracts.
Research presented at ASH 2024 highlighted the importance of absolute monocyte counts after transplant.
Research presented at ASH 2024 showed that adding budesonide didn’t compromise immunologic recovery and transplant ...
A study presented at the 2024 ASH Annual Meeting suggests that a certain test may predict GI issues caused by GVHD.
Amy Pierre, RN, BSN, ANP-BC, reflects on highlights from ASH 2024 and why it's critical for advanced practitioners to attend.
An expert in pediatric GVHD shares his hopes and projections for the future of GVHD treatment and research.
Samantha Shenoy, NP, shares why it's important for nurses and APPs to consider attending the annual meeting.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, discusses the significance of ASH 2024.
The CLL12 trial included patients with treatment-naive, asymptomatic, early-stage chronic lymphocytic leukemia.
Researchers evaluated treatment patterns, blood count control, and use of phlebotomy in patients with polycythemia vera.
Lisa Hwa, APRN, CNP, DNP, MS, discusses her work with the ASH Medical Educators Institute and her conference experience.
Amy Pierre, RN, BSN, ANP-BC, shares insights and key action items from her ASH 2024 presentation on the topic.
Richard Newcomb, MD, shares insights from his ASH 2024 presentation and explains why nurses play a major role in outcomes.
Irwin Walker, MBBS, shares how he's seen the meeting evolve since his first time attending in 1971.
An ASH 2024 presentation of data from the Myelofibrosis and Essential Thrombocythemia Observational Study provided insights.
The study highlighted that adding abatacept to CNI/MTX-based GVHD prophylaxis showed durable central outcomes post-HCT.
Kirk R. Schultz, MD, FCAHS, explains that multiple strategies for GVHD prevention and preemption are under investigation.
Risk factors for GVHD and its severity differ by donor type following allogeneic SCT with post-transplant PTCy prophylaxis.
Patients with pulmonary comorbidities and a history of smoking are at increased risk for chronic GVHD.
Dr. Bose joined Cancer Nursing Today at ASH 2024 to share insights on using anemia-supporting medications with ruxolitinib.
Piyanuch Kongtim, MD, PhD, shares insights from work she presented at the 2024 ASH Annual Meeting.
Samantha Shenoy, NP, speaks about her experience at the meeting and key highlights in multiple myeloma research.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, explains key takeaways from her myeloma research at ASH 2024.
Irwin Walker, MBBS, joined Cancer Nursing Today at ASH 2024 to share his insights on the pilot trial and the next steps.
Patient-reported outcomes increased the risk of health care utilization and HCT-related complications, like GVHD, post HCT.
Chronic GVHD is less frequent in children than in adults, but its frequency has come down much more significantly in adults.
Noah Merin, MD, PhD, explains how the GVHD prophylaxis method has changed outcomes and shares nursing implications at ASH.
The study, presented at ASH 2024, showed that none of the patients experienced grade 3-4 GVHD.
Metabolite profiles may be promising as predictive biomarkers for clinical outcomes in patients post-HSCT at risk of GVHD.
A study presented at ASH evaluated GVHD and NRM outcomes in patients who received allogeneic transplant after CAR-T.
An analysis presented at ASH 2024 suggests the summation of evidence supports the therapy as a new standard of care.
Research presented at ASH showed that baseline fatigue and depression were associated with acute GVHD.
Orca-Q showed promising efficacy, safety, and low GVHD rates in patients with high-risk hematologic malignancies.
Research presented at ASH 2024 provides novel insights into GVHD pathogenesis and potential therapeutic strategies.
They developed and validated day 28 refined response criteria for first-and second-line treatment in grades II-IV acute GVHD.
A researcher who will present on patient-reported outcomes and GVHD outcomes discusses the importance of the meeting.
Learn what researchers found about the real-world use of belumosudil as a treatment for chronic GVHD.
A new study is highlighting the importance of fiber intake after allogeneic transplantation.
GVHD risk can be assessed through serial monitoring by clinical response and biomarkers during steroid treatment.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.